Heidelberg/Berlin, July 24 2025. Precisis, a Heidelberg-based MedTech innovator developing personalized neurostimulation technology for neurological disorders, announced today the closing of a €20 million venture loan from the European Investment Bank (EIB). This funding complements the company’s recently started efforts to raise an additional €37 million in equity financing as part of its Series B round. Only a few European MedTech Companies have received this level of EIB support to date.
The EIB’s investment underscores the transformative potential of EASEE®, Precisis’ lead product. This is a CE-certified, minimally invasive neurostimulator for focal epilepsy already approved and reimbursed in Europe and the UK. By providing targeted therapy through a patient-friendly implant with proven clinical efficacy and comfort, Precisis is well-positioned for rapid commercial expansion across the UK and Europe, alongside preparations to enter the U.S. market. Building on this foundation, Precisis is also already developing a next-generation system that will utilise advanced artificial intelligence to enable a closed-loop neurostimulation approach, capable of real-time monitoring and adaptive therapy tailored to each patient’s unique needs. The EIB’s support validates Precisis’ clinical and commercial progress, bolstering confidence in its ability to advance neurological care.
